Melanoma DNA vaccine - PowderJect
Latest Information Update: 24 Sep 2021
At a glance
- Originator PowderJect Pharmaceuticals
- Class Cancer vaccines; DNA vaccines
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 20 May 2004 No development reported - Phase-I for Malignant melanoma in USA (Intradermal)
- 24 Oct 2001 A study has been added to the Cancer immunogenicity section
- 11 Aug 2000 Preliminary results from a phase I trial have been added to the adverse events section and the Cancer therapeutic trials section